Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

BACKGROUND: Liraglutide 3.0 mg, with diet and exercise, produced substantial weight loss over 1 year that was sustained over 2 years in obese non-diabetic adults. Nausea was the most frequent side effect. OBJECTIVE: To evaluate routinely collected data on nausea and vomiting among individuals on lir...

Descripción completa

Detalles Bibliográficos
Autores principales: Lean, M E J, Carraro, R, Finer, N, Hartvig, H, Lindegaard, M L, Rössner, S, Van Gaal, L, Astrup, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010971/
https://www.ncbi.nlm.nih.gov/pubmed/23942319
http://dx.doi.org/10.1038/ijo.2013.149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010971/
https://www.ncbi.nlm.nih.gov/pubmed/23942319
http://dx.doi.org/10.1038/ijo.2013.149

Ejemplares similares